Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors. (October 2022) - Fontana, E.; Williams, A.; Falchook, G.; Lakhani, N.; Evans, T.R.J.; Gondi, V.; Iwamoto, F.; McKean, M.; Symeonides, S.; Butowski, N.; McLaren, A.; Henry, J.; et al.